We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biohaven Pharmaceutical reported the U.S. Food and Drug Administration (FDA) has authorized the initiation of clinical trials for oral zavegepant (formerly BHV-3500) and the company has achieved first in human dosing in a Phase 1 trial designed to ...